Navigation Links
Cancer Experts Meet in Boston to Discuss a Promising Approach to Treating the Disease
Date:10/21/2013

CAMBRIDGE, Mass., Oct. 21, 2013 /PRNewswire/ -- Academics, healthcare providers, and pharmaceutical industry professionals are gathered in Boston to discuss the latest advances in cancer research. The evening of Tuesday, October 22, those professionals are invited to attend a symposium that will explore one of the most exciting targets in cancer treatment, a protein called hypoxia-inducible factor-1a, or HIF-1a.

The role of HIF-1a in solid tumors has been well documented. It is often present in solid tumors where hypoxic, or low oxygen, conditions are common, and its presence may be increased by anti-angiogenic medicines and radiation. Because HIF-1a can promote resistance, leaders in government, academia, and industry have long sought an effective HIF-1a inhibitor. This week, experts will discuss whether the potential of HIF-1a inhibition is soon to become a reality.

The pre-clinical panel features Giovanni Melillo, MD, of AstraZeneca and formerly of the National Cancer Institute; Sarah Conley, PhD, of MedImmune and formerly of the Max Wicha Lab at the University of Michigan; Amato Giaccia, PhD, of Stanford University; and Robert Kerbel, PhD, of the University of Toronto.

The clinical panel features William Kaelin, MD, of Harvard Medical School; Laura Benjamin, PhD, of Eli Lilly; Mark Dewhirst, DVM, PhD, of Duke University School of Medicine; and Steve Keefe, MD, of the Abramson Cancer Center at the University of Pennsylvania.

Oliver Fetzer, PhD, President and CEO of symposium sponsor, Cerulean Pharma, will welcome attendees, and Robert A. Weinberg, PhD, of the Massachusetts Institute of Tech
'/>"/>

SOURCE Cerulean Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Potential Treatment for Three Chemotherapy Resistant Cancers
2. Data Presented For ENMD-2076 In Preclinical Models Of Triple-Negative Breast Cancer
3. Nucletron, an Elekta Company, Receives U.S. FDA 510(k) Clearance for Esteya Electronic Brachytherapy System for Treating Skin Cancer
4. IceCure Enters a New High-Potential Market: The company received $100K-order for cryoablation consoles and probes to be used in a clinical study for the treatment of lung cancer
5. Sedationless Colonoscopy Option May Increase Colorectal Cancer Screening Compliance
6. Hologic to Mark Start of Breast Cancer Awareness Month with NASDAQ Opening Bell Ceremony
7. First urine-based cancer mutation monitoring test available from Trovagene
8. Warnings for Hepatitis B Reactivation in Cancer Patients Welcomed by the American Association for the Study of Liver Diseases
9. Varians Calypso Tumor Tracking System Used in Lung, Stomach and Prostate Cancer Treatments at Leading European Cancer Center
10. Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
11. Improving Outcomes in the Treatment and Management of Metastatic Colorectal Cancer - International White Paper Launched at European Cancer Congress 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 24, 2015 Hospira, Inc. (NYSE: ... of biosimilar therapies, spoke about the importance of extrapolation ... Generics Association (EGA) annual European Biosimilars Group conference in ... also announced the publication of a pivotal white paper ... full promise of biosimilars." Speaking at ...
(Date:4/24/2015)... Mass. , April 24, 2015  Blueprint ... BLU-554, a selective and potent inhibitor of fibroblast ... activity in models of hepatocellular carcinoma (HCC) that ... therapeutic candidate, BLU-554 induced complete tumor regression in ... an FGFR4-activating ligand at the highest dose levels. ...
(Date:4/23/2015)... IRVINE, Calif., April 23, 2015  Edwards Lifesciences Corporation (NYSE: ... of heart valves and hemodynamic monitoring, today reported net ... million, or $1.12 per diluted share.  Net income for ... or $0.56 per diluted share, and non-GAAP net income ... Net sales for the quarter ended March 31, 2015 ...
Breaking Medicine Technology:Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3Edwards Lifesciences Reports First Quarter Results 2Edwards Lifesciences Reports First Quarter Results 3Edwards Lifesciences Reports First Quarter Results 4Edwards Lifesciences Reports First Quarter Results 5Edwards Lifesciences Reports First Quarter Results 6Edwards Lifesciences Reports First Quarter Results 7Edwards Lifesciences Reports First Quarter Results 8Edwards Lifesciences Reports First Quarter Results 9Edwards Lifesciences Reports First Quarter Results 10Edwards Lifesciences Reports First Quarter Results 11Edwards Lifesciences Reports First Quarter Results 12Edwards Lifesciences Reports First Quarter Results 13Edwards Lifesciences Reports First Quarter Results 14Edwards Lifesciences Reports First Quarter Results 15Edwards Lifesciences Reports First Quarter Results 16
...  Reportlinker.com announces that a new market ... catalogue: Triple Analysis: ... http://www.reportlinker.com/p0284888/Triple-Analysis-Apoptosis-Cancer-Vaccines-and-Antibodies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This ... development strategies by the two mechanism/target/effect ...
... Research Institute (IDRI) announces today that GlaxoSmithKline (GSK) Biologicals ... equipment that will assist IDRI as it designs and ... the developing world. IDRI will apply the gift as ... tuberculosis, leishmaniasis, malaria, leprosy, and pandemic influenza. ...
Cached Medicine Technology:Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 2Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 3Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 4Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 5GlaxoSmithKline Donates Scientific Equipment to Advance IDRI's Global Health Mission 2
(Date:4/25/2015)... New Jersey (PRWEB) April 25, 2015 ... people aged twelve and above needed treatment for an ... according to the Substance Abuse and Mental Health Services ... September 2011). Beyond these alarming numbers are harrowing stories ... by substance abuse . David H. Kerr ...
(Date:4/25/2015)... April 25, 2015 The federal ... mesh lawsuits filed against C.R. Bard, Inc. continues ... Southern District of West Virginia. According to a ... was convened that day, after certain defendants submitted ... Complaint. The Order directed that any Preliminary Motions ...
(Date:4/25/2015)... Carinsurancequotesinfo.com has released a new blog post that ... for flatbed trucks. , Flatbed trucks are ... They are mainly used for commercial purposes and thus ... explains that by comparing multiple offers, drivers can find ... vehicles. , It is now possible to compare free ...
(Date:4/25/2015)... By definition, a CIO’s responsibility is to support the ... their judgement and expertise to keep digital assets and environments ... article published in National Mortgage News on April 22nd, 2015 ... to their responsibilities by focusing too heavily on making sure ... it comes to company policy and industry best practices, and ...
(Date:4/25/2015)... The impact of the Trivedi Master ... of the public and is likely to cause further, ... and June. From March 21st to March 31st, ... "Special Prayers." More than 600 people participated in the ... and have reported intense experiences that they attest have ...
Breaking Medicine News(10 mins):Health News:New Book Features Powerful Stories of People Who Overcame Addiction 2Health News:New Book Features Powerful Stories of People Who Overcame Addiction 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 4Health News:Auto Insurance Quotes for Flatbed Trucks Available Online! 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 2Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 3
... The following is a,statement of SEIU spokesperson Andrew McDonald:, ... health and,vitality of any democratic organization., "For the last ... and full debate over the future of our union. For ... been the subject of,an even more vigorous debate -- in ...
... China, April 8, 2008 /Xinhua-PRNewswire-FirstCall/ --,Linkwell Corporation (Linkwell ... developer, manufacturer and distributor of healthcare related,disinfectants in ... year-end,financial results in a conference call on Wednesday, ... Company will release its 2007 year-end financial results ...
... rising on,everything from bread to education, and health care is ... a Medicaid patient in the home, the,urgent need for an ... to nurses and other home care advocates,visiting legislators today as ... cost of a nurse,s visit to a home care patient ...
... Mark your calendars for these,training and networking ... Detroit Chapter (IABC/Detroit)!, April 16 Luncheon Session: ... organization,s message impact its market,share? Find out when ... messaging has impacted today,s marketing landscape., Join ...
... School of Medicine and colleagues at Merck Serono Research ... receptor sites on some tumors in different places at ... combination therapy for certain types of cancer. , An ... called epidermal growth factor receptors (EGFR) sitting on their ...
... Newborns Vulnerable for Rare,Metabolic Conditions, WASHINGTON, April 8, ... the Bills to four consecutive Super,Bowls, will be on ... with,Members of Congress asking them to approve and fund ... also participate in a press event with Senators Christopher,Dodd ...
Cached Medicine News:Health News:Linkwell Corporation Year-End 2007 Earnings Release and Conference Call Notice 2Health News:Bayada Nurses Advocates for Increase in Medicaid Reimbursement Rate to Allow More Individuals to Receive Home Care and Hire More Skilled Staff 2Health News:IABC/Detroit Announces April Professional Development and Networking Events 2Health News:Double binding sites on tumor target may provide future combination therapy 2Health News:Pro Football Hall of Fame Member Jim Kelly Urges Congress to Approve the Newborn Screening Saves Lives Act 2Health News:Pro Football Hall of Fame Member Jim Kelly Urges Congress to Approve the Newborn Screening Saves Lives Act 3Health News:Pro Football Hall of Fame Member Jim Kelly Urges Congress to Approve the Newborn Screening Saves Lives Act 4
Bio-Rad's ScanGel® cards for ABO reverse grouping, antibody screening and crossmatching include - ScanGel Neutral, ScanGel Coombs, Anti-IgG, -C3d (AHG), ScanGel Coombs + Neutral, ScanGel Anti-Ig...
... The Criterion Dodeca cell, a component of ... run up to 12 Criterion gels in a ... (13.3 x 8.7 cm) than the traditional mini ... strips to give you the optimal combination of ...
... Dodeca cell accommodates up to 12 large ... runs in the PROTEAN IEF system, for ... The PROTEAN Plus Dodeca cell's cooling and ... allow consistent, high-resolution results. The handcasting system ...
... ElectroXpress gel electrophoresis system mirrors a 96-well ... screening of PCR products to take place ... source (96-well) plate. Loading can be carried out ... first time in the industry two sets ...
Medicine Products: